➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Johnson and Johnson
Mallinckrodt
McKinsey
Baxter

Last Updated: May 28, 2020

DrugPatentWatch Database Preview

ZEVALIN Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for ZEVALIN

Identify potential brand extensions & biosimilar entrants

SponsorPhase
National Cancer Institute (NCI)Phase 3
University of California, DavisPhase 2
Duke UniversityPhase 2

See all ZEVALIN clinical trials

Recent Litigation for ZEVALIN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
GENENTECH, INC. v. CELLTRION, INC.2018-01-12
GENENTECH, INC. v. SANDOZ, INC.2017-12-21
Biogen Idec, Inc. v. Glaxosmithkline LLC2010-03-24

See all ZEVALIN litigation

Company Disclosures: US Patents for ZEVALIN

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial Idec Pharmaceuticals Corporation (San Diego, CA) 2015-04-07 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceuticals Corporation (San Diego, CA) 2015-07-07 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial 2015-12-01 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceuticals Corporation (San Diego, CA) 2039-03-29 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ZEVALIN

These patents were identified by searching patent claims

Supplementary Protection Certificates for ZEVALIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
93138 Luxembourg   Start Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
C300424 Netherlands   Start Trial PORDUCT NAME: RITUXIMAB; NAT. REGISTRATION NO/DATE: 19980602; FIRST REGISTRATION: CH IKS 54378 01 19971127
CA 2004 00021 Denmark   Start Trial PRODUCT NAME: IBRITUMOMAB TIUXETAN
16/2004 Austria   Start Trial PRODUCT NAME: IBRITUMOMAB TIUXETAN; REGISTRATION NO/DATE: EU/1/03/264/001 20040116
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
McKinsey
Dow
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.